Trials / Unknown
UnknownNCT05509478
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma：a Multicenter,Single-arm,Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- The First Hospital of Jilin University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, single-arm,phase Ⅱ study to evaluate the efficacy and safety of Lenvatinib in combination with PD-1 inhibitors as first-line treatment in patients with unresectable advanced Biliary Tract Carcinoma (BTC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | 8 mg once daily (QD) oral dosing. |
| DRUG | PD-1 inhibitors | Regular dose intravenously every 3 weeks |
Timeline
- Start date
- 2022-08-20
- Primary completion
- 2023-02-01
- Completion
- 2023-09-01
- First posted
- 2022-08-22
- Last updated
- 2022-09-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05509478. Inclusion in this directory is not an endorsement.